FLG and Alzheimer disease: Interestingly, the Janus kinase inhibitor, JTE-052, now the main ingredient in an ointment called Delgocitinib, was originally reported to induce filaggrin expression, and this ointment has been deployed as topical therapy for AD (49, 50), suggesting that targeting keratinocyte functions is one potential strategy for treating AD.